- $473.31m
- $549.31m
- $170.44m
Regenxbio falls after FDA extends review of genetic disorder therapy
Regenxbio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Regenxbio Inc - Phase Iib/Iii Trial To Be Initiated For Diabetic Retinopathy
Biotech firm Regenxbio Q2 net loss widens
Regenxbio Inc expected to post a loss of $1.10 a share - Earnings Preview
Regenxbio Inc expected to post a loss of $1.10 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
U.S. STOCKS ON THE MOVE-Owens & Minor ,Scinai , Vermilion Energy
U.S. STOCKS ON THE MOVE-PVH, Phio Pharma, Cracker Barrel
Regenxbio rises on early data from muscle disorder gene therapy trial
Brief: Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202
Brief: Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million
Brief: FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment
Brief: Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii
Regenxbio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Regenxbio Q1 Net Income USD 6.083 Million
Regenxbio Inc expected to post earnings of 48 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gilead Sciences, Plug Power, BGM Group
Regenxbio rises on early data from gene therapy for muscle disorder